ArticleFuture science OA2016
Citrate functionalized Mn
Article in Future science OA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 49 citations in OpenAlex.
- Breaking the ROS inflammation loop: a hierarchical nanozyme natural enzyme cascade for acetaminophen induced acute liver injury.Journal of nanobiotechnology · 2026Article
- Magnesium oxide nanoparticles: A novel shield against CCl₄-induced hepatic damage via caspase-3 and TNF-α in rats.Open veterinary journal · 2026Article
- The Dual-Faceted Role of Metal-Based Nanomaterials in Hepatic Fibrosis Therapy.International journal of nanomedicine · 2026Review
- Chitosan functionalized MnCommunications biology · 2023Article
- Understanding the Potential Role of Nanotechnology in Liver Fibrosis: A Paradigm in Therapeutics.Molecules (Basel, Switzerland) · 2023Review
- Insights on drug and gene delivery systems in liver fibrosis.Asian journal of pharmaceutical sciences · 2023Review
- Chemoprevention of bilirubin encephalopathy with a nanoceutical agent.Pediatric research · 2023Article
- Stress mechanism involved in the progression of alcoholic liver disease and the therapeutic efficacy of nanoparticles.Frontiers in immunology · 2023Review
- A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders.iScience · 2022Article
- Implementation of surface functionalization of MnS nanoparticles for achieving novel optical properties and improving therapeutic potential.RSC advances · 2022Article
- Green Synthesis of Silymarin-Chitosan Nanoparticles as a New Nano Formulation with Enhanced Anti-Fibrotic Effects against Liver Fibrosis.International journal of molecular sciences · 2022Article
- Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Review
- Redox nanomedicine ameliorates chronic kidney disease (CKD) by mitochondrial reconditioning in mice.Communications biology · 2021Article
- MnSaudi journal of biological sciences · 2021Article
- Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis.Nanomaterials (Basel, Switzerland) · 2020Review
- Novel one pot synthesis and spectroscopic characterization of a folate-MnRSC advances · 2019Article
- Manganese Oxide Nanozymes Ameliorate Mechanical Allodynia in a Rat Model of Partial Sciatic Nerve-Transection Induced Neuropathic Pain.International journal of nanomedicine · 2019Article
- Spectroscopic Studies on Dual Role of Natural Flavonoids in Detoxification of Lead Poisoning: Bench-to-Bedside Preclinical Trial.ACS omega · 2018Article
- Biologically synthesized metal nanoparticles: recent advancement and future perspectives in cancer theranostics.Future science OA · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo test the potential of orally administered citrate functionalized Mn MATERIALS &
methodsC-Mn
resultsWe demonstrated ultrahigh efficacy of the C-Mn
conclusionThese findings may pave the way for practical clinical use of the NPs as safe medication of chronic liver diseases associated with fibrosis and cirrhosis in human subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.